Log in

DarioHealth Stock Forecast, Price & News

+1.54 (+8.85 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $18.95
50-Day Range
MA: $16.07
52-Week Range
Now: $18.95
Volume162,187 shs
Average Volume135,864 shs
Market Capitalization$159.56 million
P/E RatioN/A
Dividend YieldN/A
DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. It offers Dario Engage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications, and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy and distributors; and through e-stores. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.95 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:DRIO



Sales & Book Value

Annual Sales$7.56 million
Book Value$8.45 per share


Net Income$-17,740,000.00
Net Margins-293.20%


Market Cap$159.56 million
Next Earnings Date10/26/2020 (Estimated)
OptionableNot Optionable
+1.54 (+8.85 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DRIO News and Ratings via Email

Sign-up to receive the latest news and ratings for DRIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

DarioHealth (NASDAQ:DRIO) Frequently Asked Questions

How has DarioHealth's stock price been impacted by Coronavirus (COVID-19)?

DarioHealth's stock was trading at $6.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DRIO stock has increased by 175.0% and is now trading at $18.95.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of DarioHealth?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DarioHealth

When is DarioHealth's next earnings date?

DarioHealth is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for DarioHealth

How were DarioHealth's earnings last quarter?

DarioHealth Corp (NASDAQ:DRIO) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.86. The company had revenue of $1.79 million for the quarter, compared to the consensus estimate of $1.72 million. DarioHealth had a negative return on equity of 165.09% and a negative net margin of 293.20%.
View DarioHealth's earnings history

What price target have analysts set for DRIO?

3 Wall Street analysts have issued 1-year target prices for DarioHealth's stock. Their forecasts range from $10.00 to $25.00. On average, they expect DarioHealth's stock price to reach $17.33 in the next year. This suggests that the stock has a possible downside of 8.5%.
View analysts' price targets for DarioHealth

Are investors shorting DarioHealth?

DarioHealth saw a increase in short interest in August. As of August 31st, there was short interest totaling 162,200 shares, an increase of 109.3% from the August 15th total of 77,500 shares. Based on an average daily trading volume, of 261,600 shares, the short-interest ratio is presently 0.6 days. Approximately 3.2% of the shares of the stock are short sold.
View DarioHealth's Short Interest

Who are some of DarioHealth's key competitors?

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include AEterna Zentaris (AEZS), Vascular Biogenics (VBLT), NANO DIMENSION/S (NNDM), Pluristem Therapeutics (PSTI), CorMedix (CRMD), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

Who are DarioHealth's key executives?

DarioHealth's management team includes the following people:
  • Mr. Erez Raphael, CEO & Director (Age 46)
  • Mr. Olivier R. Jarry, Pres & Chief Commercial Officer (Age 58)
  • Mr. Zvi Ben David, CFO, Treasurer & Sec. (Age 58)
  • Mr. Dror Bacher, Chief Operating Officer (Age 44)
  • Ms. Joao Mendes-Roter, VP of Marketing

What is DarioHealth's stock symbol?

DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."

Who are DarioHealth's major shareholders?

DarioHealth's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Meitav Dash Investments Ltd. (2.27%) and Goldman Sachs Group Inc. (0.72%). Company insiders that own DarioHealth stock include Adam K Stern, Allen Kamer, Erez Raphael, Hila Karah and Yoav Shaked.
View institutional ownership trends for DarioHealth

Which major investors are buying DarioHealth stock?

DRIO stock was acquired by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., and Goldman Sachs Group Inc.. Company insiders that have bought DarioHealth stock in the last two years include Adam K Stern, Allen Kamer, Erez Raphael, Hila Karah, and Yoav Shaked.
View insider buying and selling activity for DarioHealth

How do I buy shares of DarioHealth?

Shares of DRIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DarioHealth's stock price today?

One share of DRIO stock can currently be purchased for approximately $18.95.

How big of a company is DarioHealth?

DarioHealth has a market capitalization of $159.56 million and generates $7.56 million in revenue each year. The company earns $-17,740,000.00 in net income (profit) each year or ($8.00) on an earnings per share basis. DarioHealth employs 69 workers across the globe.

What is DarioHealth's official website?

The official website for DarioHealth is www.mydario.com.

How can I contact DarioHealth?

DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company can be reached via phone at 972-4770-4055 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.